Replies to post #127032 on Biotech Values

[DewDiligence]

Clearly, the NVS-MNTA Lovenox agreement from 2003 did not foresee MNTA’s owning IP capable of blocking a competitor’s entry into the market. That’s why I think the sharing of legal expenses in this instance is unclear.